MET amplification increases the metastatic spread of EGFR-mutated NSCLC. (November 2018)

• Record Type: Journal Article
• Authors: Baldacci, Simon; Kherrouche, Zoulika; Cockenpot, Vincent; Stoven, Luc; Copin, Marie Christine; Werkmeister, Elisabeth; Marchand, Nathalie; Kyheng, Maéva; Tulasne, David; Cortot, Alexis B.
• Is Part Of: Lung cancer. Volume 125(2018)
• Page Start: 57
• Page End: 67
• Publication Date: 2018-11
• Subjects: Non small cell lung cancer -- EGFR -- MET -- Tyrosine kinase inhibitor -- Metastasis; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2018.09.008
• Languages: English
• ISSNs: 0169-5002

Abstract

Highlights: MET amplification enhances proliferation of EGFR mutated NSCLC cells in vitro . MET amplification also promotes cell migration and EMT phenotype. In vivo, MET amplification increases tumor growth and metastatic spread. Abstract: Background: Five to 20% of metastatic EGFR-mutated non-small cell lung cancers (NSCLC) develop acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKI) through MET amplification. The effects of MET amplification on tumor and patient phenotype remain unknown. Methods: We investigated, in vitro and in vivo, the impact of MET amplification on the biological properties of the HCC827 cell line, derived from an EGFR-mutated NSCLC. We further evaluated the time to new metastases after EGFR-TKI progression in EGFR-mutated NSCLC, exhibiting MET amplification or high MET overexpression. Results: MET amplification significantly enhanced proliferation, anchorage independent growth, anoikis resistance, migration, and induced an epithelial to mesenchymal transition. In vivo, MET amplification significantly increased the tumor growth and metastatic spread. Treatment with a MET-TKI reversed this aggressive phenotype. We found that EGFR-mutated NSCLC patients exhibiting MET amplification on a re-biopsy, performed after EGFR-TKI progression, displayed a shorter time to new metastases after EGFR-TKI progression than patients with high MET overexpression but no MET amplification. Conclusion: MET amplification increases metastatic spread even in the context of an already pre-existing strong driver mutation such as EGFR mutation. These results prompt development of therapeutic strategies aiming at preventing emergence of MET amplification.